Category Archives: Biochemistry

Oncologists who specialize in differentiated thyroid cancer (DTC) commonly use the American Thyroid Association (ATA) 2015 guidelines for risk stratification in patients. A real-world study assessed the performance of this system in patients with DTC and discovered that the system is reliable for predicting short-term outcomes.

The ATA risk stratification system is a reliable predictor of short-term outcomes in patients with DTC in real-world clinical settings characterized by appreciable treatment-center heterogeneity in terms of size, location, level of care, diagnostic resources, and local management strategies, Durante et al concluded, in the paper.

A report published inThyroid provided prospective 1-year data from 2000 patients who were treated in the real-world across 50 centers throughout Italy. Patients were found in the Italian Thyroid Cancer Observatory, an online database governed by the Thyroid Cancer Center of the Sapienza University of Rome. To be selected for the study, each patient record was required to have a histological diagnosis of DTC, papillary thyroid cancer (PTC), follicular thyroid cancer (FTC), or poorly DTC and variants of these diseases. All patients were also required to have available information on treatment and pathological characteristics for investigators to determine their risk using the ATA risk stratification system. The third and final requirement was full information about each patients 1-year follow-up visit which was needed to estimate response to treatment.

Following the exclusion of 4610 cases from the database of 6867, the final cohort was compiled of 2071 patients from 40 centers. In 1109 patients (53.6%), the ATA risk of persistent and/or recurrent disease was classified as low, 796 patients (38.4%) were classified as intermediate risk, and 166 (8.0%) were classified as high risk.

Investigators led by Cosimo Durante, MD, found that in the overall population, 1576 patients (76.1%) had an excellent response, 376 (17.8%) had an indeterminate response, 33 (1.6%) had a biochemical incomplete responses, and structural incomplete responses were found in 86 patients (4.2%), which showed progressive increase with the baseline risk levels estimated as 1.5% in the low-risk patients, 5.7% in intermediate-risk patients, and 14.5% in high-risk patients. Prior treatment did impact responses to treatment at 1-year evaluation.

Of the patients with prior radioactive iodine remnant ablation, excellent responses were observed in 921 (77.3%), indeterminate responses were seen in 168 (14.1%), biochemical incomplete responses were observed in 33 (2.8%), and structural incomplete responses were observed in 69 patients (5.8%). Among those who had a total thyroidectomy, 655 (81.1%) had excellent responses, 137 (17%) had indeterminant responses, no patients had a biochemical incomplete response, and structural incomplete responses were seen in 15 patients (1.9%). Finally, among patients who had a thyroid lobectomy, 71 patients (97.3%) had an indeterminant response and 2 (2.7%) had a structural incomplete response. No patients in the thyroid lobectomy group had an excellent response or biochemical incomplete response.

A significant predictor of response to treatment was determined to be ATA risk class assigned at baseline, which was observed again at 1-year follow-up. There was no data for the low-risk group; however, the odds ratios (OR) for response to treatment in the intermediate-risk group was 4.67 (95% CI, 2.59-8.43;P<.0001). In the high-risk group, the OR was 16.48 (95% CI, 7.87-34.5;P<.0001). The results also showed a high probability of suboptimal response in patients classified as intermediate- to high-risk. Specifically, the OR that intermediate-risk patients would have a response to treatment was 1.68 (95% CI, 1.34-2.10;P<.0001). The OR that high-risk patients would respond was 3.23 (95% CI, 2.23-4.67;P<.0001).

Another assessment conducted during the study looked at how individual practice reporting impacted the performance of initial disease risk. The assessment included both academic and non-academic cancer centers. No impact was found.

Our findings demonstrate that the ATA risk stratification system for recurrent/persistent disease is indeed a reliable predictor at the 1-year follow-up evaluation, independent of treatment centers. This is true in spite of the fact that the likelihood of a less-than-excellent response varies across treatment centers, probably as a result of between-center differences in surgical volumes, case mixes, the availability of diagnostic tools, and/or other factors, wrote Durante et al.

Reference:

Durante C, Grani G, Zaelli MC, et al. Real-world performance of the American Thyroid Association risk estimates in predicting 1-year differentiated thyroid cancer outcomes: A prospective multicenter study of 2000 patients. Thyroid. Published online July 1, 2020. doi: 10.1089/thy.2020.0272

See the article here:
Is ATA Risk Stratification Still a Reliable Predictor of Response in DTC? - Targeted Oncology

The research report on Automated Biochemical Analyzers market comprises of insights in terms of pivotal parameters such as production as well as the consumption patterns alongside revenue estimations for the projected timeframe. Speaking of production aspects, the study offers an in-depth analysis regarding the manufacturing processes along with the gross revenue amassed by the leading producers operating in this business arena. The core objective of the Automated Biochemical Analyzers market report is to help organizations gain aa better understanding of this business sphere in terms of the key growth drivers, restraints, and opportunities influencing the market dynamics.

According to the report, the market is projected to expand with a CAGR of XX% over the review period 2020-2025.

In the midst of the lockdown due to the COVID-19 pandemic, several industries have been forced to halt their operations which has dealt a major blow to their revenues. Some of them are projected to face challenges even after the economy recovers.

Request Sample Copy of this Report @ https://www.express-journal.com/request-sample/184545

Majority of businesses have realigned their priorities and revised their budget to ensure profitability in the forthcoming years. Our all-inclusive analysis of this industry suggests reliable strategies to help you draft a strong action plan for the future.

Further, the research report forecasts revenues and assesses the trends of each sub-market to identify the prospects of this market.

Major highlights of the Automated Biochemical Analyzers market report:

Automated Biochemical Analyzers Market segments covered in the report:

Regional segmentation: North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia), South America (Brazil, Argentina, Colombia) and Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa).

Product categories:

Market share of each product type based on their sales and revenue.

Application spectrum:

Competitive outlook:

Basic company details, manufacturing sites, and competitors of each company

Highlights of the Report:

Request Customization on This Report @ https://www.express-journal.com/request-for-customization/184545

Original post:
Global Automated Biochemical Analyzers Market Size, Share, Trends, CAGR by Technology, Key Players, Regions, Cost, Revenue and Forecast 2020 to 2025 -...

In 2011, at the age of 57, Stanford biochemistry professor Pat Brown took a leap faith and quit his job to launch plant-based "meat" company Impossible Foods. He did it because wanted to help solve one of the world's biggest problems before he retired.

"The use of animals as a technology in food production is, by a huge margin, the most destructive technology on earth in the history of our species," Brown tells CNBC Make It.

Today, Impossible Foods, best known for its juicy, meat-tasting vegan burger, is valued at more than $4 billion. Its burgers are served in more than 17,000 restaurants worldwide, including via partnership deals withBurger King, White Castle and Starbucks. It's also sold in8,000 grocery stores,

Here, Brown talks withCNBC Make It about his life before Impossible Foods, his first investor pitch meeting and where he sees the brand going. The interview has been edited together for length and clarity.

CNBC Make It: Today, you are the founder of Impossible Foods. But talk to me about life before Impossible Foods.

Pat Brown: I grew up assuming that I ever did about 50% of my childhood was in the Washington, D.C. suburbs and the other 50% was split in Paris [France] and in Taipei [Taiwan]. And I wasn't a very good student. I was capable, but I had very little interest in school. Fortunately, when it was time for me to go to college [in the 1980s], it was a time when the fraction of people who tried to go to college was a lot lower. So I was able to get into the University of Chicago, which is where I went for undergrad and then I stayed there for my M.D. and Ph.D. [in biochemistry].

I wanted to have more of tangible impact on the world ... so I decided to go into biomedical research. And then I did a pediatrics residency, so I spent three years as a pediatrician in Chicago, at Children's Memorial Hospital. I'd have a 36-hour non-stop day. But I loved it because you felt every moment like you were helping people.

Let's move forward to 2009. You were 57 and a professor at Stanford Medicine, Stanford University's medical school, and you took a sabbatical. How did that lead to the creation of Impossible Foods?

I used the [sabbatical] to try to figure out, what's the most important problem in the world is that I might be able to contribute to solving? The use of animals as a technology in food production is, by a huge margin, the most destructive technology on Earth in the history of our species. And once I realized that, it was a no-brainer.

Relatively quickly it became clear that you are not going to solve the [meat consumption] problem by regulation, education or trying to persuade people. Even most environmentalists that go to climate and environmental conferences are eating steak for dinner. They're not going to stop eating foods that are a big source of pleasure in their daily lives.

So that meant that the only way to solve the problem is to understand what consumers love about these foods and do a better job of delivering it than the current industry does. That means competing in the marketplace and pulling the economic rug out from under that industry. I had to start a company to make those changes and that's why I founded Impossible Foods.

What was your first pitch to get funding for Impossible Foods like?

You can't walk a block in Palo Alto [California, where Stanford is located] without tripping over a venture capitalist. I went to talk to three of the big VC firms but I was naive about what drives venture investors. It's not the same thing that drives me, it turns out.

The message that really snapped them to attention is that the there was, at that time, a $1.5 trillion global market being served by a technology [meat production] that has fundamentally not been improved since prehistoric times. And it's just waiting to be taken down by better technology.

But that was kind of like my last [pitch deck] slide. Now, I am much more upfront about this, saying that is a humongous prize for whoever can develop the technology to replace animals in the food system.

How did you create the Impossible Burger?

The premise was this is a scientific problem. We needed to understand in molecular detail how meat works.

From a nutritional standpoint, the problem was already solved [by plant-based] protein. Just to put it in perspective, the global soybean crop occupies .8% of Earth's land area and produces 150% as much protein as in all the meat consumed globally. And it uses way less fertilizer, pesticides and water than the animal agriculture industry. And it's cheaper by far.

The unsolved problem is deliciousness. So we had to study: What makes meat delicious?

We hired molecular biologists, biochemist, biophysicist and basic scientists because the the problem was not making food. It was understanding how this particular food works to create those emergent properties that people crave. So, they got started working on understanding what makes meat delicious.

And how did you find the magic ingredient, heme?

When you cook meat some kind of magical happens there's an explosion of aroma and it's flavor profile becomes completely different. When you have an explosion of chemical activity like that, to me that suggests that there was a catalyst in there.

What I knew was that heme besides being the molecule that carries oxygen in your blood making it red is one of the best catalysts in nature. And it's staring right at you, because it's responsible for the red or pink color of meat. So, it's just screamingly obvious.

You can basically take vegetable broth but if you throw in heme, it tastes like meat.

When you first introduced Impossible Burger, why did you market it to restaurants as opposed to consumers?

We debuted it with a handful of world renowned, uncompromising chefs, the first of which was Dave Chang, who once made a big splash by banning on principle every vegetarian item from his menu. So this guy is a meat guy to the bone, and the perfect person for us to launch with. Someone like Dave Chang, Traci Des Jardins, Brad Farmer and Chris Cosentino, these very meat-focused chefs, wanted it on their menus. So you would be insane not to take advantage of that.

Where do you see Impossible Foods going?

I think last year we increased our sales by about threefold. This year, it's very likely to be more than twofold. In order to achieve our mission[to eliminate the need to make food from animals], we have to grow on average about twofold every year for the next 15 years.

More than 90% of the people who ever want impossible burger are current meat eaters. We need to convince them to try [Impossible Burger]. Once we do that, I think we're in.

Check out:Americans spend over $5,000 a year on groceriessave hundreds at supermarkets with these cards

Don'tmiss:

Beyond Meat CEO on early naysayers: A new idea is crazy until its not

Whole Foods CEO on plant-based meat boom: Good for the environment but not for your health

Impossible CEO on critics who say plant-based meat is unhealthy: 'It's bull----'

Excerpt from:
Impossible Foods CEO on finding meat's magical ingredient, pitching VCs and convincing meat-loving chefs to serve a vegan burger - CNBC

Data Bridge Market Research has recently published the Global research Report Titled: Chitosan Market

Chitosan Market report is an excellent report that makes it possible to the Chitosan industry can be highly benefited with this market research report which brings market and competitive landscape clearly into the focus and help make better decisions. Market segmentation has also been performed in detail based on various parameters that include applications, verticals, deployment model, end user, and geography. Expert solutions combined with potential capabilities prepare this winning Chitosan Market document to be outperforming for the Chitosan

Data models employed for the research methodology are vendor positioning grid, market time line analysis, market overview and guide, company positioning grid, company market share analysis, standards of measurement, top to bottom analysis and vendor share analysis. Not to mention, the data is collected only from the dependable sources such as journals, newspapers, company websites and annual reports of the companies on which Chitosan industry can rely confidently. Businesses are highly relying on the different segments covered in the market research report which gives better insights to drive the business into right direction. The market studies, insights and analysis carried out in this credible Chitosan Market research report keeps marketplace clearly into the focus which helps achieve business goal.

The latest report includes Impact of Coronavirus(Covid-19) on the Chitosan Industry, it includes on Industry Upstream, Industry Downstream, Industry Channels, Industry Competition, and finally on Industry Employment.

Get PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-chitosan-market

(***Our Free Sample Copy of the report gives a brief introduction to the research report outlook, TOC, list of tables and figures, an outlook to key players of the market and comprising key regions.***)

Global chitosan market is expected to register a healthy CAGR of 14.8% in the forecast period of 2019-2026. The rise in the market value can be attributed to the growing awareness about health globally, unique properties of chitosan and availability of abundant raw material. The report contains data of the base year 2018 and historic year 2017.

The Leading Market Players Covered in this Report are :

Panvo Organics Pvt Ltd, Qingdao Yunzhou Biochemistry co., ltd., , Advanced Biopolymers AS, meron, Heppe Medical Chitosan GmbH, Kitozyme, LLC, Kraeber & Co. GmbH, Foodchem International Corporation, FMC Corporation, Golden-Shell Pharmaceutical, Primex EHF, Nano3Bio, KOYO CHEMICAL CO.,LTD., Dainichiseika Color & Chemicals Mfg. Co., Ltd., Biothera Pharmaceuticals among others.

Market Definition: Global Chitosan Market

Chitosan is a kind of carbohydrate that is bonded with number of sugar molecules. It contains chitin and chitosan, which are two naturally abundant and renewable polymers that shows varied properties like non-toxicity, adsorption, nature-friendly and biodegradability. The compound is used for various applications particularly in the industries like agrochemicals, water treatment and cosmetics.

Market Drivers:

Market Restraints:

Regional Analysis Includes:

The Report published on Data Bridge Market Research about Chitosan Market is spread across several pages and provides newest industry data, market future trends, allowing you to identify the products and end users driving revenue growth and profitability. The industry report lists and studies the leading competitors, also provides the insights with strategic industry analysis of the key factors influencing the market dynamics.

Chitosan Market Research Report is a professional and in-depth study on the current state which focuses on the major drivers and restraints for the key players. Industry research report provides granular analysis of the market share, segmentation, revenue forecasts and geographic regions of the market.

Find More Competitor in TOC with Profile Overview Share Growth Analysis @ https://www.databridgemarketresearch.com/toc/?dbmr=global-chitosan-market

Segmentation: Global Chitosan Market

By Source

Grade

ByApplication

Key Insights Of The Report:

Key Questions Answered:

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.databridgemarketresearch.com/speak-to-analyst/?dbmr=global-chitosan-market

Some of the major objectives of this report:

1) To provide a detailed analysis of the market structure along with the forecast of the various segments and sub-segments of the global Chitosan Market.

2. To provide insights about factors affecting market growth. To analyze the Chitosan Market based on various factors- price analysis, supply chain analysis, porter five force analyses, etc.

3. To provide historically and forecast revenue of the Chitosan Market segments and sub-segments with respect to four main geographies and their countries- North America, Europe, Asia, and the Rest of the World.

4. Country-level analysis of the market with respect to the current market size and future prospective.

5. To provide country-level analysis of the market for segment by application, product type and sub-segments.

6. To provide strategic profiling of key players in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market.

7. Track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the Chitosan Market.

Customization Available : Global Chitosan Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.

About Us:

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to complex business challenges and initiates an effortless decision-making process.

Contact:

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

[emailprotected]

View post:
Chitosan Market : Global Industry Analysis By Size, Growth Rate, Share, Covid-19 Impact And Trends With Forecast To 2020 2026 | Leading Players-...

The National Academy of Inventors has named two University of Georgia faculty members to the 2020 class of NAI Senior Members.

Richard Meagher, Distinguished Research Professor of Genetics, and Ronald Orlando, professor of biochemistry and molecular biology, and chemistry, are the first UGA researchers to receive the senior membership distinction. They join a new class of 38 prolific inventors representing 24 research universities along with government and nonprofit research institutes worldwide.

Meagher has dedicated nearly five decades to performing pioneering research across several diverse biotechnology disciplines, including plant molecular genetics, monoclonal antibody development and epigenetics. His research contributions at UGA have led to 58 invention disclosures, eight issued U.S. patents and one pending U.S. application. Hes also co-founded four biotechnology companies based on these technologies. One company, Abeome, is developing therapeutic antibodies against inflammatory and other diseases. Meagher received the UGA Inventors Award in 2004 and the UGA Entrepreneurs Award in 2017.

Consistent encouragement by my colleagues and the creative environment at UGA have been essential to this recognition by NAI and much of my success as an inventor and entrepreneur, said Meagher.

Orlando joined the Complex Carbohydrate Research Center in 1993 and leads a prominent research group dedicated to glycobiology and biochemistry. He holds two U.S. patents and four pending patent applications and has appeared as an inventor on 17 invention disclosures ranging from software to novel compounds and methods of analysis. Orlando has launched three startup companies based on UGA-licensed technology that have raised more than $7.8 million in funding and launched 57 new products. He serves as CEO of GlycoScientific, an Innovation Gateway resident company developing research tools and potential therapeutic antibodies for cancer, and was the inaugural recipient of the UGA Entrepreneurs Award in 2010.

I am deeply honored to have been elected as a senior member of the National Academy of Inventors, but I am not the only person deserving recognition for this honor, Orlando said. Innovation Gateway provided the guidance and infrastructure I needed to move my research into the marketplace.

Innovation Gateway is a key component of the universitys Innovation District initiative to cultivate a comprehensive innovation ecosystem that supports research commercialization, entrepreneurship, industry engagement and experiential learning.

The NAI Senior Member program recognizes national and international academic inventors who have demonstrated success in developing new technologies that benefit society. Senior members are elected biennially and undergo a rigorous selection process by the NAI Advisory Committee, which is composed of elected NAI members and other professionals considered pioneers in their respective fields.

Follow this link:
Two UGA professors named to National Academy of Inventors - WGAU

Clinical Biochemistry Analyzer Market Research

The Clinical Biochemistry Analyzer Market 2020 report includes the market strategy, market orientation, expert opinion and knowledgeable information. The Clinical Biochemistry Analyzer Industry Report is an in-depth study analyzing the current state of the Clinical Biochemistry Analyzer Market. It provides a brief overview of the market focusing on definitions, classifications, product specifications, manufacturing processes, cost structures, market segmentation, end-use applications and industry chain analysis. The study on Clinical Biochemistry Analyzer Market provides analysis of market covering the industry trends, recent developments in the market and competitive landscape.

It takes into account the CAGR, value, volume, revenue, production, consumption, sales, manufacturing cost, prices, and other key factors related to the global Clinical Biochemistry Analyzer market. All findings and data on the global Clinical Biochemistry Analyzer market provided in the report are calculated, gathered, and verified using advanced and reliable primary and secondary research sources. The regional analysis offered in the report will help you to identify key opportunities of the global Clinical Biochemistry Analyzer market available in different regions and countries.

The final report will add the analysis of the Impact of Covid-19 in this report Clinical Biochemistry Analyzer industry.

To know How COVID-19 Pandemic Will Impact This Market/Industry-Request a sample copy of the report https://www.reportsandmarkets.com/sample-request/global-clinical-biochemistry-analyzer-market-research-report-2020?utm_source=startupng&utm_medium=41

The report scrutinizes different business approaches and frameworks that pave the way for success in businesses. The report used Porters five techniques for analyzing the Clinical Biochemistry Analyzer Market; it also offers the examination of the global market. To make the report more potent and easy to understand, it consists of info graphics and diagrams. Furthermore, it has different policies and development plans which are presented in summary. It analyzes the technical barriers, other issues, and cost-effectiveness affecting the market.

GlobalClinical Biochemistry AnalyzerMarket Research Report 2020 carries in-depth case studies on the various countries which are involved in the Clinical Biochemistry Analyzer market. The report is segmented according to usage wherever applicable and the report offers all this information for all major countries and associations. It offers an analysis of the technical barriers, other issues, and cost-effectiveness affecting the market. Important contents analyzed and discussed in the report include market size, operation situation, and current & future development trends of the market, market segments, business development, and consumption tendencies. Moreover, the report includes the list of major companies/competitors and their competition data that helps the user to determine their current position in the market and take corrective measures to maintain or increase their share holds.

Key questions answered in this report

Reasons for Buying this Report

This report provides pin-point analysis for changing competitive dynamics

It provides a forward looking perspective on different factors driving or restraining market growth

It provides a six-year forecast assessed on the basis of how the market is predicted to grow

It helps in understanding the key product segments and their future

It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors

It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

TABLE OF CONTENT:

Chapter 1:Clinical Biochemistry Analyzer Market Overview

Chapter 2: Global Economic Impact on Industry

Chapter 3:Clinical Biochemistry Analyzer Market Competition by Manufacturers

Chapter 4: Global Production, Revenue (Value) by Region

Chapter 5: Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6: Global Production, Revenue (Value), Price Trend by Type

Chapter 7: Global Market Analysis by Application

Chapter 8: Manufacturing Cost Analysis

Chapter 9: Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10: Marketing Strategy Analysis, Distributors/Traders

Chapter 11: Clinical Biochemistry Analyzer Market Effect Factors Analysis

Chapter 12: GlobalClinical Biochemistry Analyzer Market Forecast to 2027

Get Complete Brochure @ https://www.reportsandmarkets.com/sample-request/global-clinical-biochemistry-analyzer-market-research-report-2020?utm_source=startupng&utm_medium=41

About Us:

Reports And Marketsis part of theAlgoro Research Consultants Pvt. Ltd.and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Are you mastering your market? Do you know what the market potential is for your product, who the market players are and what the growth forecast is? We offer standard global, regional or country specific market research studies for almost every market you can imagine.

Contact Us:

Sanjay Jain

Manager Partner Relations & International Marketing

http://www.reportsandmarkets.com

Ph: +1-352-353-0818 (US)

Read more:
Global Clinical Biochemistry Analyzer Market 2020: Competitive Landscape Analysis and Future Outlook by Companies, Key Regions, Types and Application...